1-cyclohexyl-3,3-dimethylbutan-2-one | 23137-42-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-cyclohexyl-3,3-dimethylbutan-2-one
• 英文别名: 2.2-Dimethyl-4-cyclohexyl-butanon-(3)；1-Cyclohexyl-3.3-dimethylbutanon-2
• CAS: 23137-42-0
• 化学式: C₁₂H₂₂O
• 分子量: 182.306
• InChiKey: YKMNILHGXBTYGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  B-cyclohexyl-9-borabicyclo<3.3.1>nonane 、 1-溴频哪酮 生成 1-cyclohexyl-3,3-dimethylbutan-2-one
  参考文献：
  名称：

  Reaction of B-alkyl-9-borabicyclo[3.3.1]nonanes with .alpha.-bromo ketones under the influence of potassium tert-butoxide. A convenient procedure for the .alpha.-alkylation of ketones

  摘要：

  DOI：

  10.1021/ja01036a070

文献信息

• NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS
  申请人：MetCalf, III Chester A.

  公开号：US20100184649A1

  公开（公告）日：2010-07-22

  The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against Clostridium difficile.

  本发明涉及新型脂肽化合物，这些化合物的药物组合物以及使用这些化合物作为抗菌化合物的方法。本发明的化合物特别适用于对抗各种细菌，包括耐药菌株。这些化合物可用作抗Clostridium difficile的抗菌剂。
• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20090048297A1

  公开（公告）日：2009-02-19

  The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R 1 -R 9 , R 16 , R 18 , R 19 , n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

  该发明提供了Formula I的4-氨基-4-氧代丁酰肽化合物及其药用盐和水合物。变量R1-R9、R16、R18、R19、n、M和Z在此处定义。Formula I的某些化合物可用作抗病毒剂。本文披露的某些4-氨基-4-氧代丁酰肽化合物是有效和/或选择性抑制病毒复制的药物，特别是乙型肝炎病毒的复制。该发明还提供含有一种或多种4-氨基-4-氧代丁酰肽化合物和一种或多种药用载体的药物组合物。这种药物组合物可能仅含有4-氨基-4-氧代丁酰肽化合物作为唯一活性剂，也可能含有一种或多种其他药用活性剂与含有4-氨基-4-氧代丁酰肽的肽化合物的组合。该发明还提供了治疗哺乳动物病毒感染的方法，包括乙型肝炎感染。
• Non‐Diazo C−H Insertion Approach to Cyclobutanones through Oxidative Gold Catalysis
  作者：Zhitong Zheng、Youliang Wang、Xu Ma、Yuxue Li、Liming Zhang

  DOI：10.1002/anie.202003698

  日期：2020.9.28

  Cyclobutanones are synthetically versatile compounds that often require extensive effort to access. Herein, we report a facile synthesis of cyclobutanones based on the C(sp3)−H insertion chemistry of oxidatively generated gold carbenes. Various cyclobutanones were obtained in synthetically useful yields from substrates with minimal structural prefunctionalization. This discovery reveals new synthetic utilities

  环丁酮是合成用途广泛的化合物，通常需要付出大量努力才能获得。在此，我们报告了一种基于氧化生成的金卡宾的 C(sp 3 )-H 插入化学的环丁酮的简便合成。从具有最少结构预官能化的底物以合成有用的产率获得各种环丁酮。这一发现揭示了金催化炔酮氧化转化的新合成效用。
• L-ALANINE DERIVATIVES
  申请人：Kettle Grant Jason

  公开号：US20090111828A1

  公开（公告）日：2009-04-30

  The present invention relates to compounds that inhibit of a5 b 1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5 b 1 and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，含有其作为活性成分的制药组合物，以及它们作为药物的使用和用于制造药物以治疗温血动物（如人类）中具有显著血管生成或血管成分的疾病，如固体肿瘤的治疗。本发明还涉及抑制a5b1并且对其他整合素具有适当选择性特征的化合物。
• Substituted hydroxamic acids and uses thereof
  申请人：Blackburn Christopher

  公开号：US20110046157A1

  公开（公告）日：2011-02-24

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物： 其中R1、R2、G、n、p和q的值如说明书所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明中的化合物的制药组合物以及使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或紊乱的方法。